You searched for "outcomes"

1562 results found

What you learn after performing 10,000 cataracts

What do you do when the anterior chamber shallows, or the zonules give way? How do you handle the stubborn epinuclear plate? Raymond Radford shares the benefit of his experience when dealing with tricky cataract surgery. Firstly, you realise you...

My Top Five: Innovations in the diagnosis of ocular tumours

Ocular tumours can vary widely in origin, from benign growths to metastases from distant disseminated malignancies. Although rare, ocular tumours pose a significant health and economic burden globally, with ocular cancers accounting for 0.2% of all diagnosed malignancies in the...

Effects of phacoemulsification on IOP and drug use in glaucoma

For patients with comorbid cataract and primary open-angle glaucoma (POAG), guidance is lacking as to whether cataract extraction and traditional filtering surgery should be performed as a staged or combined procedure. Achieving this guidance requires an evidence-based understanding of the...

Intravitreal ranibizumab for the treatment of myopic CNV

The authors conducted a prospective study. Sixty-four patients (65 eyes) attended the 12-month follow-up examination. The mean patient age was 47.8 years. Fifty-five patients (86.0%) were females. All patients had pathologic myopia (a spherical equivalent of more than − 6.0...

Visual performance of new multifocal IOL

Multifocal IOLs (MIOLs) keep evolving to try and get the best outcome in terms of vision and reduction of side-effects. This prospective interventional study was carried out on 34 eyes of 17 patients (11 women (65%) and six men (35%))...

Epiretinal membranes in uveitic macular oedema

Epiretinal membrane (ERM) formation in uveitic macular oedema is a fairly common structural complication of the retina. The authors describe a retrospective case series of 104 eyes of 77 patients with uveitic macular oedema from a tertiary centre. The treatment...

IVTA use in Behçet’s disease

This study aimed to evaluate the efficacy and safety of intravitreal triamcinolone acetonide (IVTA) injection (4mg/0.1ml) in controlling posterior segment inflammation in patients with Behçet’s disease. Medical records of consecutive patients diagnosed with Behçet’s who underwent IVTA between July 2005...

Corneal keloid: Report of natural history and Outcome of Surgical Management in Two Cases

Corneal keloids are rare and typically reported following trauma (including post-surgical) and has been reported without any trauma or previous surgery. A corneal keloid differs from a hypertrophied scar in that it occurs months/years after the injury, enlarges over time...

Comparing femtosecond laser assisted-DMEK to manual DMEK

Femtosecond laser is as a novel tool for performing precise descemetorhexis in descemet membrane endothelial keratoplasty (DMEK) surgery. In DMEK surgery, the recipient’s Descemet membrane is peeled to allow adherence of the donor DMEK tissue to the recipient’s stroma. Complete...

VIBIM Study: One-year results of treatment of DME with aflibercept using TnE

The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...

Optometrists and ophthalmologists update their joint care vision

The College of Optometrists and The Royal College of Ophthalmologists have published an updated joint vision for the continued collaboration of the two professions, to support the delivery of safe and sustainable eye care services in England.

‘Class of 2024’ graduate from SpaMedica’s STEPS programme as ophthalmic surgeon celebrates first year teaching trainees to complete over 500 cataract cases

As the latest ‘Class of 2024’ graduate from SpaMedica’s Training and Education Programme for Surgeons (STEPS), a brand-new cohort of surgical trainees will take up positions at SpaMedica hospitals nationwide. Representing the next generation of ophthalmologists, they will benefit from...